Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SGLT2 inhibition, circulating metabolites, and atrial fibrillation: a Mendelian randomization study.

Cardiovascular diabetology - 17 Oct 2023

Li Jiang, Yu Yuefeng, Sun Ying, Yu Bowei, Tan Xiao, Wang Bin, Lu Yingli, Wang Ningjian

Abstract excerpt

BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown promise in reducing the risk of atrial fibrillation (AF). However, the results are controversial and the underlying metabolic mechanism remains unclear. Emerging evidence implied that SGLT2 inhibitors have extra beneficial metabolic effects on circulating metabolites beyond glucose control, which might play a role in reducing the risk of AF....

Topics

Join the communities discussing this publication.

Atrial Fibrillation
Diabetes Mellitus, Type 2
Diabetes Treatment and Management
Genome-Wide Association Study
Glycated Hemoglobin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Mendelian Randomization Analysis

Polymorphism, Single Nucleotide

Source

Open in PubMed Open full text

Identifiers

PMID: 37848934
DOI: 10.1186/s12933-023-02019-8
PMCID: PMC10583416

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SGLT2 inhibition, circulating metabolites, and atrial fibrillation: a Mendelian randomization study.PMID 37848934Read ↗

Genetic insights into SGLT2 inhibition and atrial fibrillation: exploring the mediating role of inflammatory proteins.Semantic proximity Read ↗

SGLT2 inhibition, circulating biomarkers, and Alzheimer's disease: A Mendelian randomization study.Semantic proximity Read ↗

SGLT1 and SGLT2 inhibition, circulating metabolites, and cerebral small vessel disease: a mediation Mendelian Randomization study.Semantic proximity Read ↗

Inhibition of sodium-glucose cotransporter-2 and liver-related complications in individuals with diabetes: a Mendelian randomization and population-based cohort study.Semantic proximity Read ↗

SGLT2 inhibition, high-density lipoprotein cholesterol and aortic aneurysm: A drug-target Mendelian randomization study.Semantic proximity Read ↗

Glucokinase activator, circulating metabolites, and cardio-cerebrovascular diseases: a Mendelian randomization study.Semantic proximity Read ↗

Pharmacological targets of SGLT2 inhibition on prostate cancer mediated by circulating metabolites: a drug-target Mendelian randomization studySemantic proximity Read ↗

Diabetes mellitus, glycemic traits, SGLT2 inhibition, and risk of pulmonary arterial hypertension: A Mendelian randomization study.Semantic proximity Read ↗

Long-Term Efficacy and Safety of GLP-1R Agonist and SGLT2 Inhibitor Therapy in the General Population: A 2x2 Factorial Mendelian Randomization StudySemantic proximity Read ↗

CETP and SGLT2 inhibitor combination therapy improves glycemic controlSemantic proximity Read ↗

Deciphering the interplay between SGLT2 inhibition, CCL4, and angina pectoris: A Mendelian randomization study.Semantic proximity Read ↗

Genetic Variation in Sodium-glucose Cotransporter 2 and Heart Failure.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.